Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-06-16 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2022 Annual General Meeting (AGM) materials" for Yifang Bio-Technology (Shanghai) Co., Ltd. It contains detailed meeting notices, agenda, and attachments including the 2022 Annual Report, Board of Directors work report, Supervisory Board work report, financial statements, and budget report. The document is comprehensive and clearly intended as the materials for the Annual General Meeting, including proposals for shareholder approval. It is not the annual report itself but the AGM presentation and materials. Therefore, the document fits the category of AGM Information (AGM-R).
2023-06-16 Chinese
益方生物关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of the company 益方生物科技（上海）股份有限公司. It includes details about the meeting date, voting methods, agenda items to be discussed and voted on, and instructions for shareholders to attend and vote. The document does not contain the actual annual report or financial statements but rather the notification and meeting logistics for the AGM. The document length is 3722 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-06-08 Chinese
益方生物关于自愿披露合作方贝达药业甲磺酸贝福替尼胶囊获批上市的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval and listing of a pharmaceutical product (甲磺酸贝福替尼胶囊) developed in cooperation with another company. It details the drug's registration, collaboration terms, potential financial impacts, and risk warnings. There are no financial statements, quarterly or annual results, or detailed financial data. The document is relatively short (1767 characters) and serves as a regulatory announcement about a significant business development rather than a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material event affecting the company, without detailed financial data or report attachments.
2023-05-31 Chinese
益方生物科技（上海）股份有限公司关于召开2022年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 annual performance explanation meeting (业绩说明会) to be held on June 5, 2023. It references that the 2022 annual report was already published on April 26, 2023, and this meeting is intended to provide investors with further explanation and interaction regarding the company's 2022 financial results. The document does not contain the actual financial results or detailed financial data itself, but rather provides logistical information about the upcoming investor presentation event. Therefore, this document is best classified as an Investor Presentation (IP) announcement or notice, as it focuses on the presentation and discussion of financial results rather than the results themselves. Given the document length and content, it is not a full Annual Report (10-K) or Earnings Release (ER).
2023-05-25 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2022年持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年持续督导工作现场检查报告" (2022 Continuous Supervision On-site Inspection Report) by the sponsor institution 中信证券股份有限公司 for the listed company 益方生物科技（上海）股份有限公司. It details the sponsor's on-site inspection activities during a specific period in 2022, covering company governance, internal control, information disclosure, independence, related party transactions, use of raised funds, guarantees, major investments, and operational status. The document includes findings, opinions, and recommendations but does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a standalone audit/supervision report related to regulatory compliance and sponsor oversight, fitting the category of Audit Report / Information (AR). The document length is 2747 characters, which is substantive and not a mere announcement or certification. Therefore, the best classification is AR with high confidence. FY 2022
2023-05-18 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2022年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导跟踪报告" (2022 Annual Continuous Supervision Follow-up Report) issued by the sponsor (中信证券股份有限公司) for a company listed on the STAR Market (科创板). It discusses the company's financial performance, risks, patent disputes, R&D progress, and use of raised funds. The content includes detailed financial data, risk analysis, and operational updates for the fiscal year 2022. It is not a full annual report (10-K) but a continuous supervision follow-up report required by regulatory rules for newly listed companies, which is a type of audit or regulatory oversight report. It is not an announcement or a brief notice but a substantive report with financial and operational details. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2022
2023-05-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.